Transcode Therapeutics Inc
NASDAQ:RNAZ
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.3480
  • TODAY'S CHANGE (%)
    0.0049 (1.4282%)
  • Bid / Lots
    0.3300/ 2
  • Ask / Lots
    0.3351/ 42
  • Open / Previous Close
    0.3600 / 0.3431
  • Day Range
    0.3326
    0.3650
  • 52 Week Range
    0.2160
    18.6640
  • Volume
    190,740

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 2 hours ago by Dow Jones
      Companies Mentioned: RNAZ

      TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

      BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company(TM) committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time December 4, 2024, for its 1-for-33 reverse stock split. TransCode's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on December 4, 2024, under the current trading symbol, "RNAZ." The reverse stock split was approved by TransCode's stockholders and Board of Directors on November 22, 2024, and is intended to increase the per share trading price of the Company's common stock to enable the Company to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. There is no assurance that TransCode's common stock will meet all Nasdaq requirements for continued listing.

    • 2 hours ago by Dow Jones
      Companies Mentioned: RNAZ

      TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

      BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company(TM) committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time December 4, 2024, for its 1-for-33 reverse stock split. TransCode's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on December 4, 2024, under the current trading symbol, "RNAZ." The reverse stock split was approved by TransCode's stockholders and Board of Directors on November 22, 2024, and is intended to increase the per share trading price of the Company's common stock to enable the Company to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. There is no assurance that TransCode's common stock will meet all Nasdaq requirements for continued listing.

  • Nov 27, 2024

Peers Headlines